Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Study reveals immune characteristics of long-COVID

Researchers perform antibody profiling against SARS-CoV-2, several endemic pathogens, as well as vaccine antigens among rheumatic disease patients.

2 Oct 2022

Exploring remdesivir resistance in COVID-19-infected transplant recipients

In a new study, researchers assessed the remdesivir resistance developed in coronavirus disease 2019 (COVID-19)-infected transplant recipients.

29 Sep 2022

Why fatigue from long COVID goes beyond simply feeling tired

In a recent study posted to the medRxiv* preprint server, researchers in the Netherlands examined the role of inflammatory genes, cytotoxic T-lymphocytes (CD8+ T cells), and pro-inflammatory cytokines in long-lasting severe fatigue experienced by a large number of coronavirus disease 2019 (COVID-19) patients.

21 Sep 2022

The evolution of humoral immune responses over the course of Epstein-Barr virus infection

Researchers explored probable humoral immune mechanisms related to EBV curtailment, besides neutralization, by a systematic emphasis on antibody fragment crystallizable-functional activities over the course of EBV infections.

9 Sep 2022

Researchers present their viewpoint on the link between EBV infections and the development of MS based on a previous study

Researchers presented their viewpoint on the link between Epstein-Barr virus infections and the development of multiple sclerosis based on a previous study conducted by Bjornevik et al. published in Science.

6 Sep 2022

Review explores the involvement of the endothelium as an important underpinning of long COVID’s pathophysiology

Researchers discussed possible mechanisms and potential treatment methods for endotheliopathy observed in patients with post-acute sequelae of SARS-CoV-2 infection.

6 Sep 2022

Herpesvirus-6 and Epstein–Barr virus reactivation across acute SARS-CoV-2 patients

In a new story, scientists explored human herpesvirus-6 (HHV-6) and Epstein–Barr virus (EBV) reactivation among acute coronavirus disease 2019 (COVID-19) patients.

29 Aug 2022

What are the unique traits of Long COVID?

In a new study, researchers identified distinctive characteristics of post-acute sequelae of COVID-19 (PASC) via immune profiling.

12 Aug 2022

Doctors discover genetic and viral causes of adenoid hypertrophy in kids

RUDN doctors have discovered genetic and viral causes of a frequent ENT disease in children - adenoid hypertrophy. The results are published in Life.

11 Aug 2022

The impact of cold agglutinin syndrome on clinical presentations in COVID-19

Researchers presented two cases to highlight the impact of cold agglutinin syndrome on clinical presentations in COVID-19.

8 Aug 2022

Research progress on the three-dimensional interaction between virus and host genome

A recent study reviewed the current progress on 3D interactions between host and viral genomes.

8 Aug 2022

Study confirms link between Epstein-Barr virus and multiple sclerosis

Researchers investigate the association between Epstein-Barr virus infection and multiple sclerosis.

26 Jul 2022

What is the long-term protection against COVID-19?

A new study describes the immunologic parameters associated with protection from COVID-19.

12 Jul 2022

Remdesivir resistance in renal transplant patients with long COVID-19

A new study has reported two renal transplant cases, in which individuals, after being exposed to remdesivir, developed a resistance to the drug.

1 Jul 2022

Epstein-Barr virus can reactivate in long COVID

In a recent study posted to the medRxiv* preprint server, researchers at the University of California, San Francisco, and Monogram Biosciences examined the connections between the post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC) and Epstein-Barr virus (EBV) reactivation.

23 Jun 2022

GPR183 gene a novel drug target for severe COVID-19

In a recent study posted to the bioRxiv* pre-print server, researchers provide the first preclinical evidence of the usefulness of antagonists of G-protein coupled receptor 183 (GPR183), also known as Epstein-Barr virus-induced gene 2 (EBI2), in reducing coronavirus disease 2019 (COVID-19) severity.

17 Jun 2022